Noxopharm Receives A$5.865M R & D Tax Rebate
Filed with ASX · · 2 pages · English
Story so far
Earlier from Noxopharm
- Noxopharm Announces Leadership Transition
- Noxopharm DARRT-2 Cancer Trial Update
- Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research
- Licencing Deal Expands Noxopharm Drug Opportunities
- Retraction of Grant Announcement
Later from Noxopharm
- December 2021 Quarterly Activities Report and Appendix 4C
- Appendix 4D and Half Year 2022 Financial Report
- First Patient Treated in CEP-2 Sarcoma Trial
- Orphan Drug Designation Granted to Noxopharm by US FDA
- FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm